Lasa Supergenerics Limited (NSE:LASA)
India · Delayed Price · Currency is INR 8.04
-0.20 (-2.43%)
Feb 19, 2026, 3:29 PM IST
Lasa Supergenerics Revenue
Lasa Supergenerics had revenue of 22.17M INR in the quarter ending December 31, 2025, a decrease of -93.33%. This brings the company's revenue in the last twelve months to 669.61M, down -47.77% year-over-year. In the fiscal year ending March 31, 2025, Lasa Supergenerics had annual revenue of 1.47B with 41.20% growth.
Revenue (ttm)
669.61M
Revenue Growth
-47.77%
P/S Ratio
0.62
Revenue / Employee
10.15M
Employees
66
Market Cap
412.83M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 1.47B | 430.26M | 41.20% |
| Mar 31, 2024 | 1.04B | -259.96M | -19.93% |
| Mar 31, 2023 | 1.30B | -66.97M | -4.88% |
| Mar 31, 2022 | 1.37B | -652.53M | -32.24% |
| Mar 31, 2021 | 2.02B | 351.23M | 21.00% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Nectar Lifesciences | 16.70B |
| Sigachi Industries | 4.85B |
| Beta Drugs | 3.90B |
| Sakar Healthcare | 2.31B |
| Valiant Laboratories | 2.03B |
| Bafna Pharmaceuticals | 1.47B |
| Alpa Laboratories | 1.14B |
| Vaishali Pharma | 1.14B |